Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
31.70
+0.76 (2.46%)
Dec 9 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 31.09 - 31.92
52 week 28.25 - 37.39
Open 31.11
Vol / Avg. 29.35M/32.99M
Mkt cap 197.09B
P/E 31.65
Div/yield 0.30/3.79
EPS 1.00
Shares 6.07B
Beta 0.91
Inst. own 71%
Jan 31, 2017
Q4 2016 Pfizer Inc Earnings Release (Estimated) Add to calendar
Dec 13, 2016
Pfizer Inc at Guggenheim Boston Healthcare Conference - 12:00PM EST - Add to calendar
Dec 8, 2016
Pfizer Inc at Citi Global Healthcare Conference
Nov 1, 2016
Q3 2016 Pfizer Inc Earnings Call - Webcast
Nov 1, 2016
Q3 2016 Pfizer Inc Earnings Release
Oct 6, 2016
ICU Medical Inc Conference Call to Discuss its Acquisition of Hospira Infusion Systems from Pfizer Inc - Webcast
Sep 13, 2016
Pfizer Inc at Morgan Stanley Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '16) 2015
Net profit margin 10.12% 14.28%
Operating margin 13.09% 21.14%
EBITD margin - 38.46%
Return on average assets 3.03% 4.16%
Return on average equity 8.40% 10.22%
Employees 97,900 -
CDP Score - 90 B

Address

235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha. The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira’s One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. The Company's subsidiaries include Hospira, Inc. and Medivation, Inc.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Frank A D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 58
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business, Global Innovative Pharma Business
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 57
Bio & Compensation  - Reuters
John D. Young Group President - Global Established Pharma Business
Age: 51
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 54
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 50
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 60
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Anthony J. Maddaluna Executive Vice President, President - Pfizer Global Supply
Age: 63
Bio & Compensation  - Reuters